Comparative activity of carbapenem testing: The COMPACT study

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 5, 2011, Pages 1070-1078

  Nordmann, Patrice ^a   Picazo, Juan J ^b   Mutters, Reinier ^c   Korten, Volkan ^d   Quintana, Alvaro ^e   Laeuffer, Joerg M ^f   Seak, Joyce Chen Hian ^g   Flamm, Robert K ^e   Morrissey, Ian ^h  

^a BICÊTRE HOSPITAL   (France)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

^d MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^e JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^f Janssen Cilag   (Switzerland)

^g JANSSEN CILAG GMBH   (Germany)

^h Quotient Bioresearch Ltd   (United Kingdom)

Author keywords

Doripenem; Gram negative; Imipenem; Meropenem

Indexed keywords

DORIPENEM; IMIPENEM; MEROPENEM;

ACINETOBACTER BAUMANNII; AFRICA; ARTICLE; BACTERIUM ISOLATE; BROTH DILUTION; CZECH REPUBLIC; EGYPT; ENTEROBACTERIACEAE; EPSILOMETER TEST; ESTONIA; EUROPE; FRANCE; GERMANY; GRAM NEGATIVE BACTERIUM; GREECE; HOSPITAL PATIENT; HUMAN; INFECTION SENSITIVITY; IRELAND; ITALY; LATVIA; MIDDLE EAST; NONHUMAN; POLAND; PORTUGAL; PSEUDOMONAS; RUSSIAN FEDERATION; SLOVAKIA; SPAIN; STENOTROPHOMONAS MALTOPHILIA; TURKEY (REPUBLIC); UNITED KINGDOM;

AFRICA; ANTI-BACTERIAL AGENTS; CARBAPENEMS; CROSS INFECTION; EUROPE; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; IMIPENEM; MICROBIAL SENSITIVITY TESTS; MIDDLE EAST; THIENAMYCINS;

EID: 79954606179     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr056     Document Type: Article

References (27)

1. HPA. Antimicrobial Resistance and Prescribing in England, Wales and Northern Ireland, 2008. London: HPA, July 2008. http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1216798080469 (8 July 2010, date last accessed).
2. HPA. Surveillance of Healthcare Associated Infections Report: 2008. London: HPA, July 2008. http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1216193833496 (8 July 2010, date last accessed).
3. Suarez C, Pena C, Tubau F et al. Clinical impact of imipenem-resistant Pseudomonas aeruginosa bloodstream infections. J Infect 2009; 58: 285-90.
4. Kresken M, Hafner D, Schmitz FJ et al. for the Study Group. PEG-Resistenzstudie 2004. [in German] http://www.p-e-g.org/ag_resistenz/main.htm (8 July 2010, date last accessed).
5. Kresken M, Hafner D, Schmitz FJ et al. for the Study Group. PEG-Resistenzstudie 2007. [in German] http://www.p-e-g.org/ag_resistenz/main.htm (8 July 2010, date last accessed).
6. Livermore DM, Hope R, Brick G et al. on behalf of the BSAC Working Parties on Resistance Surveillance. Non-susceptibility trends among Enterobacteriaceae from bacteraemias in the UK and Ireland, 2001-06. J Antimicrob Chemother 2008; 62 Suppl 2: ii41-54.
7. Turner PJ. MYSTIC Europe 2007: activity of meropenem and other broad-spectrum agents against nosocomial isolates. Diagn Microbiol Infect Dis 2009; 63: 217-22.
8. Korten V, Ulusoy S, Zarakolu P et al. for the Turkish MYSTIC Study Group. Antibiotic resistance surveillance over a 4-year period (2000-2003) in Turkey: results of the MYSTIC program. Diagn Microbiol Infect Dis 2007; 59: 453-7.
9. Pascual A, Perea E, Alvarez M et al. for the Spanish MYSTIC Group. The Meropenem Yearly Susceptibility Test Information Collection antimicrobial susceptibility program in Spain: a 5-year analysis. Diagn Microbiol Infect Dis 2007; 57: 195-200.
10. Gur D, Korten V, Unal S et al. Increasing carbapenem resistance due to the clonal dissemination of oxacillinase (OXA-23 and OXA-58)-producing Acinetobacter baumannii: report from the Turkish SENTRY Program sites. J Med Microbiol 2008; 57: 1529-32.
11. Picazo JJ, Betriu C, Rodriguez-Avial I et al. Antimicrobial resistance surveillance: VIRA Study 2006. Enferm Infecc Microbiol Clin 2006; 24: 617-28.
12. Jones RN, Huynh HK, Bidenbach DJ et al. Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations. J Antimicrob Chemother 2004; 54: 144-54.
13. Doripenem [package insert]. Raritan, NJ: Ortho-McNeil Pharmaceutical, Inc., 2008.
14. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Nineteenth Informational Supplement M100-S19. CLSI, Wayne, PA, USA, 2009.
15. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twentieth Informational Supplement (June 2010 Update) M100-S20-U. CLSI, Wayne, PA, USA, 2010.
16. European Committee on Antimicrobial Susceptibility Testing. Breakpoint Tables for Interpretation of MICs and Zone Diameters, Version 1.2, December 2010. http://www.eucast.org/ (3 January 2011, date last accessed).
17. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically-Eighth Edition: Approved Standard M07-A8. CLSI, Wayne, PA, USA, 2009.
18. Imipenem-cilastin [package insert]. Whitehouse Station, NJ: Merck & Co., Inc., 2007.
19. Meropenem [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP, 2007.
20. Ikawa K, Morikawa N, Uehara S et al. Pharmacokineticpharmacodynamic target attainment analysis of doripenem in infected patients. Int J Antimicrob Agents 2009; 33: 276-9.
21. Van Wart SA, Andes DR, Ambrose PG et al. Pharmacokineticpharmacodynamic modeling to support doripenem regimen optimization for critically ill patients. Diag Microbiol Infect Dis 2009; 63: 409-14.
22. Lomaestro BM, Drusano GL. Pharmacodynamic evaluation of extending the administration time of meropenem using a Monte Carlo simulation. Antimicrob Agents Chemother 2005; 49: 461-3.
23. Filho LS, Eagye KJ, Kuti JL et al. Addressing resistance evolution in Pseudomonas aeruginosa using pharmacodynamic modeling: application to meropenem dosage and combination therapy. Clin Microbiol Infect 2007; 13: 579-85.
24. Lesho E, Wortmann G, Moran K et al. Fatal Acinetobacter baumannii infection with discordant carbapenem susceptibility. Clin Infect Dis 2005; 41: 758-9.
25. Scheetz MH, Esterly JS, Malczynski M et al. Impact of dissimilar susceptibility breakpoints for doripenem on susceptibility and carbapenem discordance for Pseudomonas aeruginosa. Diagn Microbiol Infect Dis 2009; 64: 465-7.
26. Christiansen KJ, Ip M, Ker HB et al. In vitro activity of doripenem and other carbapenems against contemporary Gram-negative pathogens isolated from hospitalised patients in the Asia-Pacific region: results of the COMPACT Asia Pacific Study. Int J Antimicrob Agents 2010; 36: 501-6.
27. Torres E, Villanueva R, Bou G. Comparison of different methods of determining b-lactam susceptibility in clinical strains of Pseudomonas aeruginosa. J Med Microbiol 2009; 58: 625-9.